Veracyte

10/12/2026

Last week, Veracyte team members alongside Christy, a person diagnosed with breast cancer, and her family showed up on the TODAY show plaza in New York City to help kick off !

The team arrived, signs in tow, to join the TODAY crowd at Rockefeller Center to help amplify the importance of breast cancer research and the people who make it possible. Breast cancer research depends on brave people who say yes to clinical trials. Their courage drives new possibilities leading to better tests and treatments for the people who come next.

Christy’s treatment journey reflects the profound impact that clinical trial participants can have on other patients. Christy, a 51-year-old premenopausal mother, was able to avoid chemotherapy after receiving a low Risk of Recurrence score on the Prosigna® Breast Cancer test and consulting with her oncologist. That treatment decision was supported by clinical evidence made possible by participants in the landmark OPTIMA trial.

🩷 HUGE thank you to Christy, her family, and everyone else who showed up to help shine a spotlight on !

📺 Check out the TODAY Plaza Cam clip here! https://www.youtube.com/watch?v=fWmGKkr4TH0&t=2321s

| |

🩷 If you'd like an opportunity to express your gratitude with breast cancer patients in clinical trials, join us in thanking the people who took part in the trial - https://www.becausetheysaidyes.com

10/06/2026

Kathryn lives in the UK with her husband, Rick. The couple have been married for 28 years and have two grown-up daughters. At 50, Kathryn was diagnosed with breast cancer after attending her first routine NHS mammogram.

She underwent a mastectomy and had some lymph nodes removed before being referred to a specialist cancer center to discuss her next steps.

According to Kathryn, during her meeting with her doctors, she learned about the trial and the possibility that she might not need chemotherapy.

“I was really surprised, as I’d just assumed I’d have to have chemo,” she says. “When I found out that I didn’t, I was over the moon.”

Instead of chemotherapy, Kathryn received other recommended treatments, including a targeted cancer drug, which she took for two years. Avoiding chemotherapy meant she was able to continue working as a teacher and maintain a routine close to her life before her diagnosis.

“I was able to keep doing the job I loved—teaching—and just got on with a life that was pretty close to how it was pre-diagnosis,” she says.

Following this experience, Kathryn says she has discovered a renewed enthusiasm for life. One of her daughters, a personal trainer and strength coach, encouraged her to start going to the gym. She also enjoys spending time in London visiting her other daughter.

“It’s given me a new zest for life,” Kathryn says. “Life is good.”

Kathryn says she had complete confidence in her clinical team and the trial and never had reservations about taking part.

“I know that without patients taking part in research, there won’t be any advances in treatment,” she says. “I was really happy to take part and would encourage other patients to say ‘yes’ too.”

🩷 In honor of , join us in thanking the people, like Kathryn, who took part in the OPTIMA trial - https://www.becausetheysaidyes.com

The OPTIMA trial found more than two-thirds of people with clinically high-risk breast cancer may safely avoid chemotherapy. Thank these courageous people.

10/02/2026

depends on brave people who say yes to clinical trials. Their courage drives new possibilities, leading to better tests and treatments for the people who come next.

🩷 So, in recognition of , please join us in thanking the people who took part in the OPTIMA trial.

| |

Based on the OPTIMA trial, more than two-thirds of people with clinically high-risk breast cancer, may safely avoid chemotherapy. The OPTIMA trial showed that the Prosigna test can be used to predict chemotherapy benefit for people with HR+ breast cancer.

| The People Who Said Yes |

4,429 people joined OPTIMA across six countries. Because they said “yes” doctors can better support personalized chemotherapy decisions and make sure that the right treatment is given to the right patients.

🩷 Share your thanks here - https://www.becausetheysaidyes.com

The OPTIMA trial found more than two-thirds of people with clinically high-risk breast cancer may safely avoid chemotherapy. Thank these courageous people.

10/01/2026

When Aileen was diagnosed with stage three breast cancer, one of her biggest concerns was how treatment would affect her livelihood and her family.

Aileen, now 65, lives in the UK with her husband, Kevin. Together, they run a dry-cleaning business where they work six days a week. They are also parents to three daughters.

Aileen took part in the OPTIMA clinical trial so that she and her doctor could better understand her breast cancer.

Since Aileen's cancer had spread to a lymph node under her arm, she was eligible for the trial and was randomly assigned to the group receiving a genomic test. Her results showed a low score, indicating that chemotherapy was unlikely to benefit her.

Aileen was able to avoid chemotherapy, and instead had a mastectomy followed by hormone therapy.

This was an enormous relief for her, as she explained: "If I had to have chemotherapy, I probably would have had to stop working and we might have lost our livelihood, which would have been disastrous."

Avoiding chemotherapy meant Aileen could continue working alongside Kevin throughout her treatment, while maintaining the activities she enjoyed and spending time with her family.

"Being able to live the best life possible during cancer treatment is so important for both your physical and mental health," she says. "I was able to do all the things I love, like going swimming three to four times a week and getting away for the weekend with Kevin."

Looking back, Aileen says she had no reservations about joining the trial.

"Science and medicine can't advance without research, so I was glad to play my part in helping people like me in the future."

🩷 In honor of Breast Cancer Awareness Month, join us in thanking the people, like Aileen, who took part in the OPTIMA trial - https://www.becausetheysaidyes.com

The OPTIMA trial found more than two-thirds of people with clinically high-risk breast cancer may safely avoid chemotherapy. Thank these courageous people.

09/30/2026

Thyroid Cancer Awareness Month is a chance to broaden our understanding not only of thyroid cancer, but also of the questions and decisions that can arise when a thyroid nodule is discovered.



After discovery, providers usually use a thyroid fine-needle aspiration (FNA) biopsy to evaluate the features of nodule cells under a microscope for potential cancer characteristics. If cancer is detected or strongly suspected, the nodule is resected and examined further. If benign, no surgery is usually needed.

However, as many as 30% of thyroid FNA biopsies do not clearly show whether a nodule is cancerous or benign. Without a clear answer, patients are left wondering if they have cancer while grappling with a heavy question:

Should I proceed with surgery just in case?

Historically, many patients with an indeterminate result proceeded to diagnostic surgery, only to learn afterward that their nodules were, in fact, benign. In fact, up to 80% of these surgeries ultimately proved unnecessary because the nodules were not cancerous.

In recognition of Thyroid Cancer Awareness Month, we created an article that examines what comes after receiving an indeterminate result, highlighting clinical data that shows how advancements in genomic testing can help resolve uncertainty for many patients. In addition, the piece provides an inside look at how Veracyte supports ongoing research efforts in thyroid cancer and nodule risk stratification.

🔗 Read our thoughts here: https://www.veracyte.com/company/blog/indeterminate-thyroid-nodule-next-steps/



Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - https://www.veracyte.com/legal/cautionary-note-regarding-forward-looking-statements/

Up to 30% of thyroid biopsies are indeterminate. This Thyroid Cancer Awareness Month, learn about indeterminate thyroid nodules and how genomic testing helps.

09/25/2026

Eight studies, including analyses from multiple clinical trials, leveraging our Decipher® Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology Annual Meeting ( ), taking place from September 26 through September 30 in Boston.

| Key Highlights |

The presentations include analyses from:

🔹 Phase II and III clinical trials

🔹 Decipher Genomic Research for Intelligent Discovery ( ) research

🔹 National real-world studies

Collectively, these presentations will further explore the potential clinical value of understanding tumor biology at the molecular level and how genomic testing can help personalize treatment decisions for patients across different stages of disease.

Of note, clinical trial analyses will specifically examine Decipher’s prognostic value in assessing disease risk and predictive value in identifying which patients may benefit from treatment intensification, including adding androgen-deprivation therapy (ADT) to radiation.

| Resources |

🔗 Read the full press release - https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-eight-decipher-focused-studies-be-presented

🔗 Event information - https://www.veracyte.com/company/event/astro-2026/

📄 Decipher Prostate test - https://www.veracyte.com/tests/decipher-prostate/providers/

📄 Decipher GRID data resource - https://www.veracyte.com/innovation/decipher-grid/

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit -
https://www.veracyte.com/legal/cautionary-note-regarding-forward-looking-statements/

09/18/2026

During Thyroid Cancer Awareness Month, Veracyte recognizes that an indeterminate thyroid nodule result often leads to critical questions about malignancy risk, the potential for unnecessary surgery, and the most appropriate next step. For these patients, every management decision begins with diagnostic clarity.

Afirma® Genomic Sequencing Classifier (GSC) delivers a clinically actionable benign or suspicious result, helping clinicians conclusively rule out surgery for many patients while providing additional variant and fusion information to help guide treatment for suspicious nodules.

More than 400,000 patients have benefited from insights provided by Afirma GSC. As the most utilized molecular test for thyroid nodules in the Medicare population based on Medicare claims data*, Afirma is trusted by healthcare providers to support informed management decisions and to provide greater confidence in patient care.

🔗 Learn how Afirma GSC can support your thyroid nodule management - https://www.veracyte.com/tests/afirma-thyroid/providers/

*Based on claims for CPT codes 81546, 0026U, 0245U as of 8/11/2026 – found at https://data.cms.gov/

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit -
https://www.veracyte.com/legal/cautionary-note-regarding-forward-looking-statements/

09/16/2026

Prostate Cancer Awareness Month (PCAM) is a time to focus on the people behind every diagnosis – and the questions, decisions, and care teams that shape each patient’s path forward. Behind every study, every test result, and every treatment decision is a person looking for answers.

With that in mind, PCAM also serves as an opportunity to reflect on how ongoing research into tools such as genomic testing are helping inform more personalized conversations about prostate cancer care.

Veracyte is incredibly proud that the Decipher® Prostate Genomic Classifier continues to help providers and patients get answers. Over the years, a wide-ranging collection of publications supports the use of the Decipher Prostate test in prostate cancer care decision-making, helping clinicians and their patients navigate treatment choices with clarity through genomic insights.

Veracyte continues to build on that foundation. This work takes time, investment, and follow-through, and reflects Veracyte’s broader commitment to helping advance prostate cancer care.

As we honor Prostate Cancer Awareness Month, our team wrote a piece to discuss the latest clinical research featuring the Decipher Prostate test and how it helps patients.

| Key Topics Covered |

🔹 How the Decipher Prostate test works

🔹 Results from the ENZAMET Trial

🔹 The latest research on predicting cancer progression

🔹 A preview of new studies being presented at ASTRO 2026

🔗 For more, read the full piece here: https://www.veracyte.com/company/blog/from-awareness-to-answers-helping-personalize-care-this-prostate-cancer-awareness-month/

| Additional Resources |

🧬 For more on the Decipher Prostate test - https://www.veracyte.com/tests/decipher-prostate/providers/

📄 Explore Decipher Prostate scientific publications - https://www.veracyte.com/resources/scientific-publications/?pg=1&per_page=20&orderby=date&order=DESC&technology=decipher-prostate-genomic-classifier&technology=decipher-prostate-grid



Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - https://www.veracyte.com/legal/cautionary-note-regarding-forward-looking-statements/

09/04/2026

Over the last three decades, advances in prostate cancer screening and molecular testing have led to significant improvements in early detection and patient outcomes. However, a prostate cancer diagnosis is often only the beginning of a long, personal journey.

On that path, patients face difficult questions, like:

🔹 What does my diagnosis mean?

🔹 How aggressive is my cancer?

🔹 What are my treatment options?

🔹 What are the risks and benefits?

🔹 Is more treatment likely to help me?

🔹 Could some treatment be avoided?

In honor of Prostate Cancer Awareness Month, we wrote an article that takes a closer look at what comes after diagnosis, addressing the patient experience and some important clinical considerations along the way. As a central part of that discussion, we address how advancements in genomic testing are helping to inform more personalized conversations about care.

🔗 Read our thoughts here - https://www.veracyte.com/company/blog/from-awareness-to-answers-helping-personalize-care-this-prostate-cancer-awareness-month/

At Veracyte, we believe patients deserve answers that reflect the biology of their disease. Through the Decipher® Prostate Genomic Classifier, we are working to help clinicians and patients navigate complex prostate cancer treatment choices with genomic insights supported by a growing body of research.



Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - https://www.veracyte.com/legal/cautionary-note-regarding-forward-looking-statements/

Honoring Prostate Cancer Awareness Month 2026, we share how prostate cancer genomic testing and new Decipher Prostate research are helping guide treatment.

05/29/2026

We are proud to announce results from the landmark independent OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) trial, led by University College London (UCL).

The results, which will be presented at the ASCO 2026 Annual Meeting, conclude that the Prosigna® Breast Risk of Recurrence (ROR) test safely guides adjuvant chemotherapy decisions in patients with early-stage, estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer.

| Impact |

The study shows for the first time, based on the Prosigna test results, that more than 2/3 of patients with clinically high-risk node-positive breast cancer, including premenopausal women and patients with 4 to 9 positive nodes, could safely forgo chemotherapy and its long-term physical and emotional side effects without compromising outcomes.

For decades, chemotherapy decisions have relied on clinical factors alone such as age, tumor size, and lymph node status. Today, many node-positive breast cancer patients still receive chemotherapy as standard of care with up to 43% of breast cancer survivors experiencing persistent nerve damage years after chemotherapy.*

The Prosigna test determines a patient's ROR score, estimates the 10-year probability of distant recurrence, and identifies patients who can benefit from chemotherapy and those who may safely avoid it.

The OPTIMA trial results deliver practice-changing evidence to inform more personalized chemotherapy decision-making. These results show that the Prosigna test can accurately predict chemotherapy benefit and guide safe de-escalation across the broadest set of patients with clinically high-risk breast cancer to-date.

Prof. Rob Stein, Lead Investigator, from UCL will present the OPTIMA trial results at the ASCO 2026 Annual Meeting.

| Presentation Details |

📅 Date and Time: Saturday, May 30 at 1:15 PM CDT

📍 Location: Breast Cancer – Local/Regional/Adjuvant, Hall B1, Abstract 500

| Resources |

📄 Read full press release - https://investor.veracyte.com/news-releases/news-release-details/landmark-optima-trial-delivers-practice-changing-evidence

🔗 Event information - https://www.veracyte.com/company/events-upcoming/asco-2026-prosigna/

🧬 More on the OPTIMA trial - https://optimabreaststudy.com/

| References |

(*) Kamgar M, et al. Prevalence and predictors of peripheral neuropathy after breast cancer treatment. Cancer Medicine. 2021;10(19):6666-6676.

This article contains forward-looking statements. These forward-looking statements involve risks and uncertainties. Please visit our website for more information: https://www.veracyte.com/legal/cautionary-note-regarding-forward-looking-statements/